Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )

Details for Australian Patent Application No. 2010324686 (hide)

Owner GENENTECH, INC.

Inventors Dennis, Mark; Polakis, Paul; Rubinfeld, Bonnee

Agent Griffith Hack

Pub. Number AU-A-2010324686

PCT Pub. Number WO2011/066503

Priority 61/384,467 20.09.10 US; 61/265,262 30.11.09 US

Filing date 29 November 2010

Wipo publication date 3 June 2011

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 47/48 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 Antineoplastic agents

C07K 16/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

G01N 33/574 Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

28 June 2012 PCT application entered the National Phase

  PCT publication WO2011/066503 Priority application(s): WO2011/066503

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010324690-Surface coating system and method

2010324685-Robotic wash monitor system